Use of CYP46a1 inhibitors to treat eye and associated diseases

TW202641533APending Publication Date: 2026-10-16SANTEN PHARMACEUTICAL CO LTD +2
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
TW114150076
Authority / Receiving Office
TW · TW
Patent Type
Applications
Current Assignee / Owner
Priority Date
2024-12-20
Filing Date
2025-12-19
Publication Date
2026-10-16

Smart Images

  • Figure TWG2TA001080752_001
    Figure TWG2TA001080752_001
  • Figure TWG2TA001080752_002
    Figure TWG2TA001080752_002
  • Figure TWG2TA001080752_003
    Figure TWG2TA001080752_003
Patent Text Reader

Abstract

The present invention relates to pharmacological agents or other techniques and procedures that inhibit the function of CYP46A1, or decrease its mRNA and / or protein expression levels to treat XFS and / or XFG.
Need to check novelty before this filing date? Find Prior Art